BioPAL is a prominent provider of advanced imaging agents, specializing in MRI contrast reagents for the life sciences sector. Their product offerings include a variety of iron-based and gadolinium-based contrast agents, which are essential for T1 and T2 imaging. In addition to MRI, BioPAL develops products for other imaging modalities, including optical, nuclear imaging, and computed tomography (CT). The company also focuses on kidney diagnostics, providing immunoassay kits designed to measure glomerular filtration rate (GFR) and effective renal blood flow (RBF), utilizing innovative kits that assess the clearance of various substances.

Furthermore, BioPAL offers unique solutions for blood flow studies through stable-isotope labeled microspheres, which serve as a cost-effective alternative to traditional radioactive and optical methods. Their Viahance™ dead-cell removal kit stands out as the only product capable of simultaneously eliminating dead cells, stripped nuclei, and free oligonucleotides from cell cultures, while being autoclaved and free from foreign proteins. BioPAL also supports cellular therapy research with products for cell labeling and tracking, including stem cell imaging using MRI, and provides ELISA kits for evaluating kidney function. These technologies reflect BioPAL's commitment to advancing research and diagnostics in the life sciences.

United States

BioPAL_

BioPAL_

Company Details